Department of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Crit Rev Oncol Hematol. 2020 Jul;151:102982. doi: 10.1016/j.critrevonc.2020.102982. Epub 2020 May 12.
SARS-CoV2 infection is an emerging issue worldwide. Cancer patient are at increased risk of infection compared to general population. On the other hand, these patients are at major risk of drug interactions caused by renal and hepatic impairment background. Because of the long-term use of chemotherapy drugs, drug interactions are important in these patients especially with SARS-CoV2 treatments now. This paper is review of reported drug interactions of current treatments for COVID-19 and anticancer agents.
SARS-CoV2 感染是全球范围内的一个新出现的问题。与一般人群相比，癌症患者感染的风险更高。另一方面，这些患者由于肾功能和肝功能受损，药物相互作用的风险很大。由于长期使用化疗药物，药物相互作用在这些患者中很重要，特别是在目前针对 SARS-CoV2 的治疗中。本文综述了目前 COVID-19 治疗药物和抗癌药物的药物相互作用报道。
